1Mackstaller LL,Alpert JS.Atrial fibrillation:a review of mechanism,etiology and therapy[J].Clin Cardiol,1997,20(7):640-650.
2Mackstaller LL,Alpert JS.Atrial fibrillation:a review of mechanism,etiology and therapy[J].Clin Cardiol,1997,20(7):640-650.
3Klotz U.Interaction potential of lercanidipine,a new vasoselective dihydropyridine calcium antagonist[J].Arzneimittelforschung,2002,52 (3):155-161.
4Mahgoub AA,Medany AH,Abdulatif AS.A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmaoodynamics and kinetics in the treatmment of patients with chronic ischemic heart failure[J].Saudi Med J,2002,23(6):725-731.
6Flockhart DA,Tanus JE.Implications of cytochrome P450 interactions when prescribing medication for hypertension[J].Ach Intern Med,2002,162(4):405-412.
6Toshi SD, Santani DD, Sheth JJ, et al. Investigation into the possible mechanisms involved in altering digoxinlevels in diabetic patients[J].India J. Physician Pharmacol,1996,40(1):65
7Lewis RP. Clinical use of serum digoxin concentrations[J]. Am J Cardiol,1992,69(3):97-100
